Detalhe da pesquisa
1.
[Determinants of the cost of initiation of insulin therapy type 2 diabetic patients in France: possible approaches to optimization]. / Déterminants des coûts du passage à linsuline en France chez le patient diabétique de type 2 : quelles pistes doptimisation ?
Sante Publique
; 28(6): 781-789, 2016 Dec 19.
Artigo
em Francês
| MEDLINE | ID: mdl-28155773
2.
Performance and patients' satisfaction with the A7+TouchCare insulin patch pump system: A randomized controlled non-inferiority study.
PLoS One
; 18(8): e0289684, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37616289
3.
An Unsafe/Safe Typology in People with Type 2 Diabetes: Bridging Patients' Expectations, Personality Traits, Medication Adherence, and Clinical Outcomes.
Patient Prefer Adherence
; 16: 1333-1350, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35642243
4.
Metformin use is associated with a reduced risk of mortality in patients with diabetes hospitalised for COVID-19.
Diabetes Metab
; 47(5): 101216, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33309936
5.
Efficacy and Safety of Switching Patients Inadequately Controlled on Basal Insulin to Insulin Glargine 300 U/mL: The TRANSITION 2 Study.
Diabetes Ther
; 11(1): 147-159, 2020 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-31782050
6.
Association between sleep disturbances, fear of hypoglycemia and psychological well-being in adults with type 1 diabetes mellitus, data from cross-sectional VARDIA study.
Diabetes Res Clin Pract
; 160: 107988, 2020 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-31866527
7.
No association between fear of hypoglycemia and blood glucose variability in type 1 diabetes: The cross-sectional VARDIA study.
J Diabetes Complications
; 33(8): 554-560, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31182337
8.
Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin: The DUAL VII Randomized Clinical Trial.
Diabetes Care
; 41(5): 1009-1016, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29483185
9.
Use of insulin degludec, a new basal insulin with an ultra-long duration of action, in basal-bolus therapy in type 1 and type 2 diabetes.
Ann Endocrinol (Paris)
; 74(5-6): 487-90, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-23978337
10.
A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: a randomized, controlled trial.
Diabetes Care
; 34(3): 669-74, 2011 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-21285389